Medication info
Janus Duo Tablets 50/500 mg (Sitagliptin Phosphate Hydrate, Metformin Hydrochloride)

Janus Duo Tablets 50/500 mg (Sitagliptin Phosphate Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
White Life Sciences Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets per bottle, 120 tablets per bottle
Approval status
Active

MFDS item code 202400671 · Approved 2024.03.27 · Insurance code 625202370

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Should Not Take This Medicine). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Take This Medicine).

Ingredients

Manufacturer
White Life Sciences Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medicine helps patients with type 2 diabetes control their blood sugar more effectively while combining dietary and exercise therapy. The components of sitagliptin and metformin work together to help manage blood sugar levels stably. Hence, it is used as an adjunct therapy in the treatment of type 2 diabetes requiring blood sugar control.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Should Not Take This Medicine). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Take This Medicine).

Precautions

This medicine consists of two components, each used for diabetes treatment. The first component is a drug that helps control blood sugar, and the second component acts to lower blood sugar. When taking this medicine, severe allergic reactions may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and notify a healthcare provider. Additionally, pancreatitis may develop, so if symptoms like abdominal pain, vomiting, or loss of appetite occur, consult a physician immediately. This medicine should not be used in patients with poor kidney function, acute heart failure or heart attack, acute infections or dehydration, and in women who are pregnant or breastfeeding. Particularly, if a diagnostic test involving iodine contrast media is planned, this medicine should be discontinued before and after the examination, resuming only after confirming normal kidney function. Rare but serious side effects such as lactic acidosis may occur during use. If abnormal symptoms such as muscle pain, difficulty breathing, fatigue, or abdominal pain appear, inform healthcare personnel immediately. Moreover, alcohol consumption can increase the risk of lactic acidosis, so avoiding alcohol is advisable. This medicine can cause hypoglycemia, hence caution is needed when skipping meals, irregular eating, or excessive exercise. The risk of hypoglycemia may increase when taken with other blood sugar-lowering agents, so blood sugar levels should be monitored frequently. During use, regular monitoring of kidney function and blood vitamin B12 levels is necessary to ensure no abnormalities, and caution is also required for patients with impaired liver function. In case of surgery, discontinue this medicine 48 hours prior to the operation, and it should be resumed only after confirming the recovery of normal kidney function post-surgery. If severe rash or blisters appear on the skin during treatment, alert a doctor immediately and seek treatment. The safety and effectiveness of this medicine have not been established in children under 18 years of age, and the elderly may require dosage adjustment and regular monitoring due to the possibility of reduced kidney function.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dermatitis, anorexia, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disturbances, itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container that is well-ventilated, and it is best kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the effectiveness of the medicine for a long time.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets per bottle, 120 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.